About
Discover the key to ideal health with nextCBD
Who is nextCBD?
nextCBD was founded by accomplished scientists committed to supplying the growing demand for CBD in the most bioavailable and usable forms possible. We have focused on the real science needed for maximizing the benefits of CBD and other super nutrients that naturally co-occur with it.
The Standard
Our CBD is sourced from agricultural hemp. We proudly make all our products in the USA. The demand for CBD-containing products is intense, global, and rapidly increasing. In fact, demand greatly exceeds current reserves, and what is available is generally of questionable or substandard quality. nextCBD will supply the growing worldwide demand for CBD with standardized products meeting Good Agricultural Practices (GAP), Good Manufacturing Practices (GMP), U.S. Food and Drug Administration (FDA), Environment, Health and Safety (EHS), and Kosher standards. To accomplish this, the Company adheres to strict operational protocols at each stage of product manufacture. This commitment positions nextCBD as the world leader in CBD standardization and quality. While no statement made about any nextCBD product has yet been evaluated by the U.S. Food and Drug Administration, our quality standards nevertheless
remain the highest achievable.
What makes nextCBD different
Our World-Renowned Scientists
have worked for years to make credible, science-based CBD products a reality. These efforts have led to the discovery and refinement of breakthrough methods for producing CBD with maximum Total Bioavailability.
Typically, as much as 95 percent of ordinary CBD is destroyed on its way to the bloodstream. Then, only a fraction of what gets there yields any effects. Without efficient Total Bioavailability™, ordinary CBD products are of limited use.
By applying sound scientific methods, our researchers in Israel at the Hebrew University of Jerusalem have made Total Bioavailability uniquely efficient.
nextCBD’s vastly superior Total Bioavailability multiplies the strength of our products far beyond the reach of competitors
This is a truly groundbreaking achievement in using CBD to improve health and longevity. Studies show that CBD coupled with our exclusive nextCBD Technology™ does not degrade in the stomach, as can ordinary or untreated CBD. Also, our patent-protected technology greatly enhances the transport of CBD to the bloodstream and then to sites in the body where it can achieve the desired response, hence, nextCBD Inside™.
nextCBD’s vastly superior Total Bioavailability multiplies the strength of our products far beyond the reach of competitors. The profound advances made by doing credible science have positioned us to be the global leader in setting industry standards for quality, performance and Total Bioavailability. The implications of our advances for transforming CBD use are beyond calculation.
Our Team
Mark J. Rosenfeld, MS, PhD
Chief Executive Officer & Chief Science Officer
- Medical Advisor, China Health Ministry
- Consultant, Cannabis Legalization and Regulatory Affairs to Multiple State Legislatures (Kentucky, Pennsylvania, New York, Utah and Oklahoma)
- US Member, Joint United Nations FAO/IAEA Committee on Transboundary Diseases (innovated a device for the molecular detection of bird flu and other influenzas)
- Founder and CEO, Seroctin Research & Technology, Inc.
- Visiting Scholar, Giant Panda Conservation and Research Center, Peking University, China discovered the key plant-derived factor necessary for successful Giant Panda reproduction, the basis to the captive breeding program that has elevated the species out of Endangered Species status)
- Founder and CEO, Impact Diagnostics, Inc.
Nissim Garti, MS, PhD
Chief Technology Officer
- Founder and Chief Executive Officer, Lyotropic Delivery Systems
- Director, Casali Institute of Applied Chemistry, The Hebrew University of Jerusalem
- Search Committee, 2013 Nobel Prize in Chemistry
- Recipient – 2016 Herjie Award (Top award for Nanotechnology Research Excellence)
- Editorial Board (Food and Functional Chemistry), Royal Academy of Chemistry, Cambridge, England
Garyn Angel
Chief Strategy Officer
- Chief Executive Officer and Founder, Magical Butter (revolutionized botanical extractions with its award-winning appliance)
- CNBC NEXT — 2014 (awarded to the “next generation” of trailblazers deemed instrumental to reshaping business, finance, science and technology over the next 25 years)
- President, ThinkMB (global think tank that combines modern science, traditional Chinese medicine and cannabinoids)
- President, G. Angel & Associates, Inc. (a leading advanced estate planning and tax specialty firm
- America’s Top Financial Planner — 2008, Reuters Advice Point
Kyle Yang, MBA
Vice President of Asia Operations & China Director
- North American Representative, China Continuing Medical Education
- General Director, Beijing Transpacific IP Technology Development
- Director, World Trade Organization Trade-Related Aspects of Intellectual Property Rights (TRIPS) Compliancy, China Patent and Trademark Office
- Among the first students from People’s Republic of China to attend Harvard University program that has elevated the species out of Endangered Species status)
- Founder and CEO, Impact Diagnostics, Inc.
Christopher Moore
Chief Operating Officer
- 31 year career with Merck (VP of Operations at Asia Pacific, VP Operations at Human Health. SVP Global Business Services)
- Accomplished senior business executive with broad international experience and a proven track record of leading complex organizations, developing strategies, implementing change and effectively executing to achieve strategic and operational results
- Executive Business Consultant and Advisor focused on helping businesses develop and implement strategic growth plans, as well as collaborating with them to increase their efficiency and effectiveness and achieve improved operating results
Sohail R. Zaidi
Chief Financial Officer
- Business Leader capable of driving sustainable change, steer international growth and deliver efficiencies across the supply chain
- Operating Partner at ProspEquity Partners
- CFO at Intech Process Automation
- COO and Executive Director at Ecopack Limited
- PLD in Business Leadership at Harvard Business School; YMP Business Management at INSEAD, France and B.Sc. in Electrical Engineering at University of Engineering and Technology, Lahore
- Mentor in Residence at the Innovation Hub, University of Florida
Sharon Levi-Garti, MS, PhD
Israel Project Coordinator
- Bioavailability Enhancement and Extraction
- Chief Technology Officer, Lyotropic Delivery Systems
- Fellow, Healthcare Technologies Innovation, Tel Aviv University Executive Program
- Fellow, Entrepreneurship and Innovation Program, 8200 EISP (Israel Startup Accelerator)
Susan Alpert, MD, PhD
Regulatory Affairs & Clinical Trials Advisor
- Director, FDA Office of Device Evaluation
- Senior Vice President − Global Regulatory Affairs, Medtronic
- Vice President − Regulatory Sciences, C.R. Baird, Inc.
- Executive Committee, Clinical Trials Transformation Initiative
- Board of Advisors, Medical Technology Leadership Forum
Perry G. Fine, MD
Medical Management & Regulatory Affairs Advisor
- President Emeritus, American Academy of Pain Medicine
- Vice President, European and North American Marketing, Gillette
- Professor or Anesthesiology (Pain Medicine and Palliative Care), University of Utah School of Medicine
- Member, FDA Advisory Board for Opioids
James R. Prochnow, Esq
Food, Drug & Nutraceutical Regulatory Counsel
- Chief Counsel, Dietary Supplement and Health Education Act of 1994
- Regulatory affairs and litigation, with an emphasis on food and drug law, advertising law and intellectual property issues
- Food and drug regulatory law, with emphasis on dietary supplements, OTC drugs, cosmetics, medical devices and homeopathic preparations
- Extensive experience in commercial, administrative and federal government litigation and administrative matters, including matters before the Food and Drug Administration, the Federal Trade Commission and various federal courts.
- Partner, Greenberg Traurig
- White House staff attorney
Lee Hollaar, PhD
Intellectual Property Strategy & Patent Management Director
- Chief Patent Consultant, U.S. Supreme Court
- Multiple Amicus (Friend of the Court) Briefs, US Supreme Court
- Fellow, Intellectual Property Unit, Judiciary Committee, US Senate
- Visiting Scholar, US Court of Appeals for the Federal Circuit
- Advisory Council, KUER – National Public Radio
Julius Ben-Ari, PhD
Research and Development Associate
- Director, Mass Spectometry & Chromatography, Institute of Plant Sciences and Genetics in Agriculture, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Israel
- Faculty, The Israel Institute for Biological Research, Israel
Giora Meyuhas, EMBA
Business Strategies and Israeli Affairs Advisor
- Israel Economic Minister to North America
- President & CEO, Gadot Petrochemicals
- Director, Baran Group
- Board of Governors, Technion ─ Israel Institute of Technology
- Director, First International Bank Israel
- Recipient, Israel Industrial Prize (Israel’s most prestigious corporate award)
- Multiple companies through IPO, acquisition & merger